Stock Ratings / Health Care / PRGO / options

VERA (35) MRVI (36) AGIO (39) PVLA (46) ⌘ Pro Terminal →

Perrigo Company plc (PRGO) Options Positioning, Max Pain & Unusual Sweeps

$15.90 -0.13% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $15.87

Perrigo Company plc (PRGO) carries a Roarable Rating of D- (Sell) with 41/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (41/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $2.21B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $15.87 (-0.21%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 3.4% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (41/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.2% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-7.7% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PRGO)Realized 20D OHLCV Swing Band: ±9%

Deterministic 5-Pillar Attribution (41/100 Composite)

🔍 WHY PRGO SCORES 41/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+10/20 pts (24% of score)

FRED Regime × Technicals: 58% of 52W Range • RSI-14 at 55.3 (BULLISH MOMENTUM)

▲ #2 Bullish Driver: Whale & Options Positioning+9/20 pts (22% of score)

20D Institutional Volume Accumulation (±9% realized swing band)

▼ #1 Drag / Risk Factor: SEC 10-K Forensic Risk5/20 pts (-15 pt drag)

Balance-sheet & 10-K footnote risk deducts 15 pts from forensic ceiling

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$15.06+10.4% Next Q

Q2 (-2Q)

Grade E$16.63-4% Next Q

Q3 (-1Q)

Grade E$15.96-0.4% Next Q

Current

Grade D-$15.90-7.2% Hist 90D α

Trajectory: E (33) → D- (41)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a PRGO Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While PRGO currently carries a cautious 41/100 (D-) rating due to SEC 10-K Forensic Risk (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($14.82) and Max Pain ($16.70) forces dealer call-delta covering toward $21.68.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $PRGO• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “PRGO Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 41%NO 59%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±9%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (PRGO)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for PRGO.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PRGO)

✓Walkthrough of PRGO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

PRGO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +34.29%📐 HORIZONTAL RANGE

2026-10-30O $16.07H $16.14L $15.42C $15.90VOL 3.35M

RES: $17.25SUP: $8.73SMA50: $14.82SMA200: $12.44

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PRGO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PRGO Butterfly Map → + Track PRGO →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -2.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on PRGO today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PRGO. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for PRGO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PRGO)

Health Care Rank #604 of 1016 ⚔️ VERA vs PRGO Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PRGO vs. VERA, MRVI, AGIO, PVLA)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Perrigo Company plc (PRGO) ranks #604 by composite RQD confidence (41/100, grade D-) and #242 by equity capitalization ($2.21B). Within this direct 5-issuer industry benchmark cohort, PRGO leads on earnings valuation at N/A trailing P/E, while PRGO leads on capital efficiency and profitability with -13.6% ROIC and 35.1% gross margin. PVLA currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with PRGO at 41/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
PRGO ACTIVE Perrigo Company plc	D-	41/100	—	35.1%	-13.6%	-0.13%	$2.21B	Benchmark Subject
VERA Vera Therapeutics Inc. (Class A)	D-	35/100	—	—	-35.0%	-1.32%	$2.20B	/vera-vs-prgo →
MRVI Maravai LifeSciences Holdings Inc. (Class A)	D-	36/100	—	18.3%	-35.0%	-0.47%	$2.20B	/mrvi-vs-prgo →
AGIO Agios Pharmaceuticals Inc.	D-	39/100	—	88.3%	-33.8%	-2.33%	$2.22B	/agio-vs-prgo →
PVLA Palvella Therapeutics Inc.	D	46/100	—	—	-27.9%	+2.79%	$2.18B	/pvla-vs-prgo →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001585364

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Perrigo Company plc (PRGO) reported GAAP revenue of $4.25B (-2.8% vs. FY2024 revenue of $4.37B , and -8.6% cumulative change since FY2023) , GAAP net income of -$1.43B, operating cash flow of $238.5M, and free cash flow of $145.1M (-40.7% YoY). On the balance sheet, PRGO closed FY2025 with $8.54B in total assets against $3.60B in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 5/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$4.25B	-$1.43B	$238.5M	$145.1M	$8.54B	$3.60B
FY2024 (FY)	2024-12-31	$4.37B	-$171.8M	$362.9M	$244.6M	$9.65B	$3.58B
FY2023 (FY)	2023-12-31	$4.66B	-$12.7M	$405.5M	$405.5M	—	—

3. PRGO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PRGO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Perrigo Company plc (NYSE: PRGO) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 41/100 at a spot price of $15.90 (-0.13% 1D, market cap $2.21B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, PRGO ranks #604 in composite RQD confidence.

How does PRGO compare to VERA and MRVI in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PRGO carries a Roarable D- (41/100 RQD), trailing P/E of N/A, gross margin of 35.1%, and ROIC of -13.6%. By comparison, VERA (Vera Therapeutics Inc. (Class A)) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $2.20B) and MRVI (Maravai LifeSciences Holdings Inc. (Class A)) posts a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $2.20B). Among the 5-stock peer group, PRGO leads on earnings multiple (N/A) while PRGO leads on capital efficiency (-13.6% ROIC).

What are the biggest fundamental strengths and SEC risk factors for PRGO?

Per PRGO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001585364), Perrigo Company plc generated $4.25B in revenue (-2.8% YoY), -$1.43B in net income, and $145.1M in free cash flow against $8.54B in total assets and $3.60B in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is PRGO trading relative to its 50-day, 200-day, and 52-week technical levels?

PRGO last traded at $15.90 (-0.13% on volume of 2,288,844 shares), positioning the stock +7.29% above its 50-day simple moving average ($14.82) and +27.81% above its 200-day simple moving average ($12.44). Across its 52-week range of $9.23 to $20.65, PRGO sits at the 58.4% percentile with a 14-day RSI of 55.3 (BULLISH MOMENTUM) and an implied next-earnings move of ±9.0% ($14.47 to $17.33).

PRGO Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is PRGO's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for PRGO.

Direct Sub-Reports: PRGO RQD Cockpit PRGO 12M Forecast PRGO Earnings & Move PRGO Dividends & DRIP PRGO Insiders & 13F PRGO Whale Options PRGO Profit Sankey PRGO News & Why